Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants [Formula presented] Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale

Ying Xian, Adrian F. Hernandez, Tina Harding, Gregg C. Fonarow, Deepak L. Bhatt, Robert E. Suter, Yosef Khan, Lee H. Schwamm, Eric D. Peterson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background Non–vitamin K antagonist oral anticoagulants (NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban) have been increasingly used as alternatives to warfarin for stroke prophylaxis in patients with atrial fibrillation. Yet there is substantial lack of information on how patients on NOACs are currently treated when they have an acute ischemic stroke and the best strategies for treating intracerebral hemorrhage for those on chronic anticoagulation with warfarin or a NOAC. These are critical unmet needs for real world clinical decision making in these emergent patients. Methods The ARAMIS Registry is a multicenter cohort study of acute stroke patients who were taking chronic anticoagulation therapy prior to admission and are admitted with either an acute ischemic stroke or intracerebral hemorrhage. Built upon the existing infrastructure of American Heart Association/American Stroke Association Get With the Guidelines Stroke, the ARAMIS Registry will enroll a total of approximately 10,000 patients (5000 with acute ischemic stroke who are taking a NOAC and 5000 with anticoagulation-related intracerebral hemorrhage who are on warfarin or a NOAC). The primary goals of the ARAMIS Registry are to provide a comprehensive picture of current treatment patterns and outcomes of acute ischemic stroke patients on NOACs, as well as anticoagulation-related intracerebral hemorrhage in patients on either warfarin or NOACs. Beyond characterizing the index hospitalization, up to 2500 patients (1250 ischemic stroke and 1250 intracerebral hemorrhage) who survive to discharge will be enrolled in an optional follow-up sub-study and interviewed at 3 and 6 months after discharge to assess longitudinal medication use, downstream care, functional status, and patient-reported outcomes. Conclusion The ARAMIS Registry will document the current state of management of NOAC treated patients with acute ischemic stroke as well as contemporary care and outcome of anticoagulation-related intracerebral hemorrhage. These data will be used to better understand optimal strategies to care for these complex but increasingly common emergent real world clinical challenges.

Original languageEnglish (US)
Pages (from-to)28-35
Number of pages8
JournalAmerican Heart Journal
Volume182
DOIs
StatePublished - Dec 1 2016

Fingerprint

Anticoagulants
Registries
Stroke
Cerebral Hemorrhage
Warfarin
N(4)-oleylcytosine arabinoside
Atrial Fibrillation
Multicenter Studies
Hospitalization
Cohort Studies
Guidelines

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants [Formula presented] Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry : Design and rationale. / Xian, Ying; Hernandez, Adrian F.; Harding, Tina; Fonarow, Gregg C.; Bhatt, Deepak L.; Suter, Robert E.; Khan, Yosef; Schwamm, Lee H.; Peterson, Eric D.

In: American Heart Journal, Vol. 182, 01.12.2016, p. 28-35.

Research output: Contribution to journalArticle

Xian, Ying ; Hernandez, Adrian F. ; Harding, Tina ; Fonarow, Gregg C. ; Bhatt, Deepak L. ; Suter, Robert E. ; Khan, Yosef ; Schwamm, Lee H. ; Peterson, Eric D. / Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants [Formula presented] Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry : Design and rationale. In: American Heart Journal. 2016 ; Vol. 182. pp. 28-35.
@article{337f03ab7f01418a80f087f4c12f842f,
title = "Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants [Formula presented] Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale",
abstract = "Background Non–vitamin K antagonist oral anticoagulants (NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban) have been increasingly used as alternatives to warfarin for stroke prophylaxis in patients with atrial fibrillation. Yet there is substantial lack of information on how patients on NOACs are currently treated when they have an acute ischemic stroke and the best strategies for treating intracerebral hemorrhage for those on chronic anticoagulation with warfarin or a NOAC. These are critical unmet needs for real world clinical decision making in these emergent patients. Methods The ARAMIS Registry is a multicenter cohort study of acute stroke patients who were taking chronic anticoagulation therapy prior to admission and are admitted with either an acute ischemic stroke or intracerebral hemorrhage. Built upon the existing infrastructure of American Heart Association/American Stroke Association Get With the Guidelines Stroke, the ARAMIS Registry will enroll a total of approximately 10,000 patients (5000 with acute ischemic stroke who are taking a NOAC and 5000 with anticoagulation-related intracerebral hemorrhage who are on warfarin or a NOAC). The primary goals of the ARAMIS Registry are to provide a comprehensive picture of current treatment patterns and outcomes of acute ischemic stroke patients on NOACs, as well as anticoagulation-related intracerebral hemorrhage in patients on either warfarin or NOACs. Beyond characterizing the index hospitalization, up to 2500 patients (1250 ischemic stroke and 1250 intracerebral hemorrhage) who survive to discharge will be enrolled in an optional follow-up sub-study and interviewed at 3 and 6 months after discharge to assess longitudinal medication use, downstream care, functional status, and patient-reported outcomes. Conclusion The ARAMIS Registry will document the current state of management of NOAC treated patients with acute ischemic stroke as well as contemporary care and outcome of anticoagulation-related intracerebral hemorrhage. These data will be used to better understand optimal strategies to care for these complex but increasingly common emergent real world clinical challenges.",
author = "Ying Xian and Hernandez, {Adrian F.} and Tina Harding and Fonarow, {Gregg C.} and Bhatt, {Deepak L.} and Suter, {Robert E.} and Yosef Khan and Schwamm, {Lee H.} and Peterson, {Eric D.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.ahj.2016.07.023",
language = "English (US)",
volume = "182",
pages = "28--35",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants [Formula presented] Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry

T2 - Design and rationale

AU - Xian, Ying

AU - Hernandez, Adrian F.

AU - Harding, Tina

AU - Fonarow, Gregg C.

AU - Bhatt, Deepak L.

AU - Suter, Robert E.

AU - Khan, Yosef

AU - Schwamm, Lee H.

AU - Peterson, Eric D.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background Non–vitamin K antagonist oral anticoagulants (NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban) have been increasingly used as alternatives to warfarin for stroke prophylaxis in patients with atrial fibrillation. Yet there is substantial lack of information on how patients on NOACs are currently treated when they have an acute ischemic stroke and the best strategies for treating intracerebral hemorrhage for those on chronic anticoagulation with warfarin or a NOAC. These are critical unmet needs for real world clinical decision making in these emergent patients. Methods The ARAMIS Registry is a multicenter cohort study of acute stroke patients who were taking chronic anticoagulation therapy prior to admission and are admitted with either an acute ischemic stroke or intracerebral hemorrhage. Built upon the existing infrastructure of American Heart Association/American Stroke Association Get With the Guidelines Stroke, the ARAMIS Registry will enroll a total of approximately 10,000 patients (5000 with acute ischemic stroke who are taking a NOAC and 5000 with anticoagulation-related intracerebral hemorrhage who are on warfarin or a NOAC). The primary goals of the ARAMIS Registry are to provide a comprehensive picture of current treatment patterns and outcomes of acute ischemic stroke patients on NOACs, as well as anticoagulation-related intracerebral hemorrhage in patients on either warfarin or NOACs. Beyond characterizing the index hospitalization, up to 2500 patients (1250 ischemic stroke and 1250 intracerebral hemorrhage) who survive to discharge will be enrolled in an optional follow-up sub-study and interviewed at 3 and 6 months after discharge to assess longitudinal medication use, downstream care, functional status, and patient-reported outcomes. Conclusion The ARAMIS Registry will document the current state of management of NOAC treated patients with acute ischemic stroke as well as contemporary care and outcome of anticoagulation-related intracerebral hemorrhage. These data will be used to better understand optimal strategies to care for these complex but increasingly common emergent real world clinical challenges.

AB - Background Non–vitamin K antagonist oral anticoagulants (NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban) have been increasingly used as alternatives to warfarin for stroke prophylaxis in patients with atrial fibrillation. Yet there is substantial lack of information on how patients on NOACs are currently treated when they have an acute ischemic stroke and the best strategies for treating intracerebral hemorrhage for those on chronic anticoagulation with warfarin or a NOAC. These are critical unmet needs for real world clinical decision making in these emergent patients. Methods The ARAMIS Registry is a multicenter cohort study of acute stroke patients who were taking chronic anticoagulation therapy prior to admission and are admitted with either an acute ischemic stroke or intracerebral hemorrhage. Built upon the existing infrastructure of American Heart Association/American Stroke Association Get With the Guidelines Stroke, the ARAMIS Registry will enroll a total of approximately 10,000 patients (5000 with acute ischemic stroke who are taking a NOAC and 5000 with anticoagulation-related intracerebral hemorrhage who are on warfarin or a NOAC). The primary goals of the ARAMIS Registry are to provide a comprehensive picture of current treatment patterns and outcomes of acute ischemic stroke patients on NOACs, as well as anticoagulation-related intracerebral hemorrhage in patients on either warfarin or NOACs. Beyond characterizing the index hospitalization, up to 2500 patients (1250 ischemic stroke and 1250 intracerebral hemorrhage) who survive to discharge will be enrolled in an optional follow-up sub-study and interviewed at 3 and 6 months after discharge to assess longitudinal medication use, downstream care, functional status, and patient-reported outcomes. Conclusion The ARAMIS Registry will document the current state of management of NOAC treated patients with acute ischemic stroke as well as contemporary care and outcome of anticoagulation-related intracerebral hemorrhage. These data will be used to better understand optimal strategies to care for these complex but increasingly common emergent real world clinical challenges.

UR - http://www.scopus.com/inward/record.url?scp=84988524995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988524995&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2016.07.023

DO - 10.1016/j.ahj.2016.07.023

M3 - Article

C2 - 27914497

AN - SCOPUS:84988524995

VL - 182

SP - 28

EP - 35

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -